Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients (Q30539596)

20 September 2017

Safety and prolonged activity of recombinant factor VIII Fc fusion protein in hemophilia A patients (English)

1 reference

20 September 2017

0 references

Coagulation factor VIII

0 references

0 references

7

1 reference

20 September 2017

Jerry S Powell

1

1 reference

20 September 2017

Neil C Josephson

2

1 reference

20 September 2017

Doris Quon

3

1 reference

20 September 2017

Margaret V Ragni

4

1 reference

20 September 2017

Gregory Cheng

5

1 reference

20 September 2017

Ella Li

6

1 reference

20 September 2017

Lian Li

8

1 reference

20 September 2017

Jennifer A Dumont

9

1 reference

20 September 2017

Jaya Goyal

10

1 reference

20 September 2017

Xin Zhang

11

1 reference

20 September 2017

Jurg Sommer

12

1 reference

20 September 2017

Justin McCue

13

1 reference

20 September 2017

Margaret Barbetti

14

1 reference

20 September 2017

Alvin Luk

15

1 reference

20 September 2017

Glenn F Pierce

16

1 reference

20 September 2017

language of work or name

English

0 references

publication date

5 January 2012

1 reference

20 September 2017

1 reference

20 September 2017

119

1 reference

20 September 2017

13

1 reference

20 September 2017

3031-3037

1 reference

Prolonged activity of a recombinant factor VIII-Fc fusion protein in hemophilia A mice and dogs

20 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

Improvements in factor concentrates

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

Prophylaxis in the haemophilia population

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

Novel associations of multiple genetic loci with plasma levels of factor VII, factor VIII, and von Willebrand factor: The CHARGE (Cohorts for Heart and Aging Research in Genome Epidemiology) Consortium

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

Rational design of a fully active, long-acting PEGylated factor VIII for hemophilia A treatment

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

Receptor-Fc fusion therapeutics, traps, and MIMETIBODY technology

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

Factor VIII and von Willebrand factor interaction: biological, clinical and therapeutic importance

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

Fusion-proteins as biopharmaceuticals--applications and challenges.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

Primary prophylaxis in children with haemophilia.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

FcRn: the neonatal Fc receptor comes of age.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

Clearance mechanisms of von Willebrand factor and factor VIII.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

Monomeric Fc fusions: impact on pharmacokinetic and biological activity of protein therapeutics

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

A passionate kiss, then run: exocytosis and recycling of IgG by FcRn.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

Assaying the circulating factor VIII activity in hemophilia A patients treated with recombinant factor VIII products

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

The hemophilias--from royal genes to gene therapy

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

Mortality among males with hemophilia: relations with source of medical care. The Hemophilia Surveillance System Project Investigators.

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

The orthopaedic status of severe haemophiliacs in Spain

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

Prophylactic treatment in Sweden--overtreatment or optimal model?

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

Haemophilia prophylaxis in young patients--a long-term follow-up

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

The impact of prophyactic treatment on children with severe haemophilia

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

Assay of factor VIII:C with a chromogenic substrate

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

Prophylaxis with Factor Concentrates in Preventing Hemophilic Arthropathy

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study

20 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

Practice patterns in haemophilia A therapy -- global progress towards optimal care

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

Issues surrounding therapeutic choices for hemophilia patients

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

Comparing outcomes of different treatment regimens for severe haemophilia

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

Barriers to compliance with prophylaxis therapy in haemophilia

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

Epidemiological survey of the orthopaedic status of severe haemophilia A and B patients in France. The French Study Group. secretariat.haemophiles@cch.ap-hop-paris.fr

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

When should prophylactic treatment in patients with haemophilia A and B start?--The German experience

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B.

26 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3646317

Pharmacokinetics of recombinant factor VIII (recombinate) using one-stage clotting and chromogenic factor VIII assay

26 November 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22223821

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1182/BLOOD-2011-09-382846

1 reference

20 September 2017

1 reference

20 September 2017

PubMed publication ID

22223821

1 reference